Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Table 3 Treatment of attacks

	Underweight BMI	Normal BMI	Overweight BMI	Obese BMI
Type of administration, n (%)^a
n	103	1261	792	415
HCP	10 (9.7)	367 (29.1)	148 (18.7)	67 (16.1)
Self	93 (90.3)	894 (70.9)	644 (81.3)	348 (83.9)
No. of icatibant injections per attack^a
n	103	1301	826	434
Mean ± SD	1.0 ± 0.2	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.4
Median (range)	1 (1–3)	1 (1–3)	1 (1–3)	1 (1–6)
No. of icatibant injections per attack, n (%)^a
n	103	1301	826	434
1	91 (88.3)	1090 (83.8)	687 (83.2)	312 (71.9)
1 + C1-INH rescue medication	9 (8.7)	83 (6.4)	85 (10.3)	73 (16.8)
2	2 (1.9)	112 (8.6)	48 (5.8)	24 (5.6)
2 + C1-INH rescue medication	0	8 (0.6)	5 (0.6)	22 (5.1)
3	1 (1.0)	6 (0.5)	1 (0.1)	2 (0.5)
3 + C1-INH rescue medication	0	2 (0.2)	0	0
6	0	0	0	1 (0.2)^b
C1-INH rescue medication, n (%)
n	104	1314	829	450
No. of attacks used C1-INH rescue	9 (8.7)	101 (7.7)^c	90 (10.9)	96 (21.3)^c,d
No. of patients used C1-INH rescue	2	29	21	16

BMI body mass index; C1-INH C1-inhibitor; HCP health care provider; SD standard deviation; n = number of attacks, excluding attacks with missing or unknown data
^aTwo patients (one normal BMI, one obese BMI) were found to be outliers because of an abnormally high rate of reinjections and rescue medication use. However, their data were included in this analysis
^bOne patient experienced an abdominal attack that lasted for 6 days; the patient was treated with one icatibant injection each day, for a total of six injections
^cWhen data from the outlier patient were excluded, 47/393 (12.0%) of attacks were treated with C1-INH. The other outlier patient did not use any rescue medication (Additional file 1: Table S3)
^dOne attack was treated with C1-INH; however, the number of icatibant injections used was unknown